Skip to main content
Premium Trial:

Request an Annual Quote

Konica Minolta Precision Medicine, Amazon Web Services Partner for Diagnostic Data Platform

NEW YORK – Japanese diagnostics firm Konica Minolta Precision Medicine said on Wednesday that it is entering a five-year collaboration with Amazon Web Services under which AWS will become the company's "preferred cloud provider" for the global buildout of its integrated diagnostic data platform, Lattice.

Under the agreement, Amazon has made an undisclosed investment in KMPM. Chestnut Securities acted as exclusive financial advisor to KMPM in the transaction.

KMPM's Lattice combines genomics, pathology, and radiology data along with other critical information to discover clinically relevant biomarkers and inform the creation of new diagnostic tests.

According to the company, the goal is to combine KMPM’s technology — which includes genomics services provided by Ambry Genetics — with AWS' machine learning, storage, compute, database, and analytics services to support customers with clinical trials at scale and develop new ways to bring clinical grade diagnostic tools directly to researchers and clinicians.

"One of the most significant challenges to the advancement of precision medicine has been the lack of an infrastructure to support translational bioinformatics," Kiyotaka Fujii, chairman of KMPM, said in a statement.

Working with AWS, "KMPM will be better positioned to innovate, collaborating with our expert team of data scientists, developers, clinicians, and pharmaceutical partners at scale, and reducing the time it takes to move from insight to discovery," he added.

KMPM, based in Tokyo, will also take advantage of AWS' secure infrastructure to process, maintain, and store protected health information in compliance with medical information guidelines in Japan.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.